IP Protection After U.S.-China Trade Deal: Patents, Trademarks, Copyrights, Trade Secrets

Ms. Burgy focuses on opinion work, client counseling, patent prosecution and management, and litigation in the chemical, pharmaceutical, and biotechnology arts. She counsels her clients on a diverse range of patent issues. She assists clients on single-patent issues as well as complex matters involving multiple patents and applications requiring ongoing advice on patent portfolio strategy and development, with an eye towards litigation. She has assisted clients in the early stages of development through due diligence and patent portfolio analysis.

Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.

Mr. Van Horn has a strong working knowledge of the specialized areas of patent reexamination, patent term extension, and procedures under the Patent Cooperation Treaty. After a 31-year career at the USPTO, he joined the firm and has served in a variety of leadership positions relating to patent policy and practice. While deputy solicitor, he argued cases in the federal courts. As deputy assistant commissioner, he established the policy and practice for examining patent applications.

Ms. Wu has significant experience in both United States and China trademark and copyright law. She advises clients and works closely with counsel around the world on trademark usage, clearance, prosecution, domestic and worldwide portfolio management, litigation, and enforcement matters. She also handles cancellation and opposition proceedings before the Trademark Trial and Appeal Board. She focuses on enforcing client rights against counterfeiters and manages anti-counterfeiting actions in China, crafting efficient solutions for each client. She also conducts searches on the Chinese trademark databases and manages Chinese trademark prosecution and enforcement matters for many publicly traded companies.

Ms. Yang focuses her practice on patent litigation and client counseling in the areas of biotechnology and pharmaceuticals, with particular emphasis on Abbreviated New Drug Application (ANDA) cases. She is involved in all phases of litigation, including pre-litigation analysis, fact discovery, and expert discovery. She also has experience in Section 337 litigation at the International Trade Commission and post-grant proceedings at the Patent Trials and Appeals Board, including inter partes reviews.